Hypofractionated whole breast irradiation after IORT treatment is safe in patients receiving adjuvant chemotherapy
Clin. transl. oncol. (Print)
; 23(12): 2579-2583, dec. 2021.
Article
in En
| IBECS
| ID: ibc-224115
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Introduction Hypofractionated whole breast irradiation (hWBI) and intraoperative radiotherapy (IORT) could be associated in breast cancer patients showing high-risk factors of local recurrence after breast conserving therapy (BSC). The aim of this trial was to evaluate, for the first time, the toxicity and cosmesis of hWBI after photon-IORT in high-risk patients treated by adjuvant chemotherapy. Materials and methods Thirty-one high-risk localized breast cancer patients treated by BCS, IORT (20 Gy), and adjuvant chemotherapy were included from February 2019 to August 2020 in this prospective trial, of hWBI (40.5 Gy/2.67 Gy/15 fractions). Acute and late toxicity (CTCAEv5.0) and cosmesis (Harvard scale), were assessed after treatment. Results All patients completed their treatment and were evaluable after treatment. No patients showed severe (G3) acute/late toxicity. Excellent/good cosmesis at least 6 months after completing the treatment, was present in 93.6% of the patients. Conclusion hWBI in high-risk localized breast cancer patients treated by chemotherapy seems to have similar toxicity and cosmetic results than conventionally fractionated WBI in combination to photon-IORT after BCS (AU)
Key words
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Breast Neoplasms
/
Mastectomy, Segmental
/
Chemotherapy, Adjuvant
Limits:
Adult
/
Aged
/
Female
/
Humans
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2021
Document type:
Article